$APMD News
Last published 1w ago
- 1w agoAPMDApnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical...
- 1w agoAPMDApnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed" or the "Company"), a late-stage clinical pharmaceutical company dedicated to the discovery, development and
- 4w agoVTVTAPMDVEEViOnctura appoints Paul Sekhri as Chair of its Board of DirectorsGlobeNewswirePaul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercializationAppointment comes as iOnctura prepares for late-stage
- 1mo agoAPMDApnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026GlobeNewswireCAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel
- 2mo agoAPMDApnimed Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireU.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi™, and assigned a PDUFA target action date of February 28, 2027 If approved, Oxnimbi has the
- 2mo agoAPMDApnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed" or the "Company"), a late stage clinical pharmaceutical company dedicated to the discovery, development and
- 3mo agoAPMDApnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswireCAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel